Arrowhead Research Corp. (ARWR) Shares Down 3.6%
Arrowhead Research Corp. (NASDAQ:ARWR) was down 3.6% on Tuesday . The stock traded as low as $5.65 and last traded at $5.68, with a volume of 117,124 shares. The stock had previously closed at $5.89.
Several equities research analysts recently weighed in on ARWR shares. Jefferies Group reaffirmed a “hold” rating and issued a $4.75 price objective on shares of Arrowhead Research Corp. in a report on Wednesday, May 11th. Vetr downgraded shares of Arrowhead Research Corp. from a “strong-buy” rating to a “buy” rating and set a $6.49 price target for the company. in a report on Wednesday, April 13th. Finally, Chardan Capital assumed coverage on shares of Arrowhead Research Corp. in a report on Thursday, May 19th. They issued a “buy” rating and a $12.00 price target for the company. Two analysts have rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company’s stock. Arrowhead Research Corp. currently has an average rating of “Buy” and an average price target of $10.27.
The company’s market cap is $335.78 million. The stock has a 50 day moving average of $5.76 and a 200-day moving average of $5.03.
Arrowhead Research Corp. (NASDAQ:ARWR) last released its quarterly earnings data on Tuesday, May 10th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.37) by $0.02. Analysts expect that Arrowhead Research Corp. will post ($1.40) earnings per share for the current year.
Arrowhead Pharmaceuticals, Inc, formerly Arrowhead Research Corporation, is a biopharmaceutical company. The Company is engaged in developing RiboNucleic Acid interference (RNAi) therapeutics. Its products include ARC-520, ARC-521, ARC-AAT, ARC-F12, ARC-HIF2 and ARC-LPA. ARC-520 is designed to treat chronic hepatitis B virus (HBV) infection.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.